AU2017346974B2 - Vaccine constructs and uses thereof against staphylococcus infections - Google Patents

Vaccine constructs and uses thereof against staphylococcus infections Download PDF

Info

Publication number
AU2017346974B2
AU2017346974B2 AU2017346974A AU2017346974A AU2017346974B2 AU 2017346974 B2 AU2017346974 B2 AU 2017346974B2 AU 2017346974 A AU2017346974 A AU 2017346974A AU 2017346974 A AU2017346974 A AU 2017346974A AU 2017346974 B2 AU2017346974 B2 AU 2017346974B2
Authority
AU
Australia
Prior art keywords
seq
polypeptide
lys
ile
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017346974A
Other languages
English (en)
Other versions
AU2017346974A1 (en
Inventor
Éric BROUILLETTE
Julie CÔTÉ-GRAVEL
François MALOUIN
Céline STER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOCPRA Sciences et Genie SEC
Original Assignee
SOCPRA Sciences et Genie SEC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOCPRA Sciences et Genie SEC filed Critical SOCPRA Sciences et Genie SEC
Publication of AU2017346974A1 publication Critical patent/AU2017346974A1/en
Application granted granted Critical
Publication of AU2017346974B2 publication Critical patent/AU2017346974B2/en
Priority to AU2022204585A priority Critical patent/AU2022204585A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2017346974A 2016-10-21 2017-10-20 Vaccine constructs and uses thereof against staphylococcus infections Ceased AU2017346974B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022204585A AU2022204585A1 (en) 2016-10-21 2022-06-28 Vaccine constructs and uses thereof against staphylococcus infections

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662411120P 2016-10-21 2016-10-21
US62/411,120 2016-10-21
PCT/CA2017/051253 WO2018072031A1 (en) 2016-10-21 2017-10-20 Vaccine constructs and uses thereof against staphylococcus infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022204585A Division AU2022204585A1 (en) 2016-10-21 2022-06-28 Vaccine constructs and uses thereof against staphylococcus infections

Publications (2)

Publication Number Publication Date
AU2017346974A1 AU2017346974A1 (en) 2019-03-14
AU2017346974B2 true AU2017346974B2 (en) 2022-03-31

Family

ID=62018642

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017346974A Ceased AU2017346974B2 (en) 2016-10-21 2017-10-20 Vaccine constructs and uses thereof against staphylococcus infections
AU2022204585A Abandoned AU2022204585A1 (en) 2016-10-21 2022-06-28 Vaccine constructs and uses thereof against staphylococcus infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022204585A Abandoned AU2022204585A1 (en) 2016-10-21 2022-06-28 Vaccine constructs and uses thereof against staphylococcus infections

Country Status (24)

Country Link
US (2) US11324815B2 (OSRAM)
EP (1) EP3529260A4 (OSRAM)
JP (2) JP7181208B2 (OSRAM)
KR (1) KR20190082229A (OSRAM)
CN (1) CN109843910A (OSRAM)
AR (1) AR109847A1 (OSRAM)
AU (2) AU2017346974B2 (OSRAM)
BR (1) BR112019007796A2 (OSRAM)
CA (1) CA3037070A1 (OSRAM)
CL (1) CL2019001048A1 (OSRAM)
CO (1) CO2019005169A2 (OSRAM)
CR (1) CR20190249A (OSRAM)
DO (1) DOP2019000102A (OSRAM)
IL (1) IL265869A (OSRAM)
MX (2) MX2019004539A (OSRAM)
MY (1) MY195369A (OSRAM)
NZ (1) NZ751880A (OSRAM)
PE (1) PE20191320A1 (OSRAM)
PH (1) PH12019500843A1 (OSRAM)
RU (2) RU2022100889A (OSRAM)
SG (2) SG10201912431XA (OSRAM)
TW (1) TW201819402A (OSRAM)
UY (1) UY37448A (OSRAM)
WO (1) WO2018072031A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113777317A (zh) * 2020-06-09 2021-12-10 首都医科大学附属北京世纪坛医院 尿液主穹隆蛋白及其多肽片段在烧伤中的应用
US20220185852A1 (en) * 2020-12-11 2022-06-16 Bayer Animal Health Gmbh Methods and compositions for improved production of an antigen for use in an s. aureus vaccine
WO2026014994A1 (ko) * 2024-07-12 2026-01-15 주식회사 더윤헬스텍 젖소 유방염 유래 대장균 또는 황색 포도알균 변이주 및 이를 포함하는 백신 조성물
US12161970B1 (en) 2024-08-09 2024-12-10 Jiaxing Research Institute, Zhejiang University CO2 desorption system suitable for limited space in complex sailing region and flexible control method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2792956A1 (en) * 2010-03-17 2011-09-22 Socpra - Sciences Et Genie, S.E.C. Bacterial vaccine components from staphylococcus aureus and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1288774C (en) 1985-01-07 1991-09-10 Deborah A. Eppstein 1,2-dialkoxy-w-trialkylammonium cationic surfactants
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US7060458B1 (en) 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
MXPA05005045A (es) 2002-11-12 2005-07-01 Brigham & Womens Hospital Vacuna de polisacarido para infecciones estafilococicas.
CN1569893A (zh) 2003-07-21 2005-01-26 中国人民解放军军事医学科学院基础医学研究所 金葡菌毒力因子调控蛋白的抗原表位及其模拟表位和用途
RU2419628C2 (ru) 2004-09-22 2011-05-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция для применения в вакцинации против стафилококков
BRPI0516974A (pt) * 2004-10-21 2008-09-30 Wyeth Corp composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis
KR100729954B1 (ko) 2004-12-01 2007-06-20 주식회사 엘지생명과학 Ｓｅｃ１ 변이 단백질의 제형 및 그것의 제형화 방법
CA2667788A1 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
EP2411046B1 (en) 2009-03-23 2017-12-06 Epitopix, LLC Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
NZ612315A (en) 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
BR112013032774B1 (pt) 2011-06-19 2020-05-05 Univ New York composições compreendendo proteína luke isolada ou polipeptídeo da mesma, uma proteína lukd isolada ou polipeptídeo da mesma ou sua combinação, bem como seu uso

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2792956A1 (en) * 2010-03-17 2011-09-22 Socpra - Sciences Et Genie, S.E.C. Bacterial vaccine components from staphylococcus aureus and uses thereof

Also Published As

Publication number Publication date
JP2019531100A (ja) 2019-10-31
CO2019005169A2 (es) 2019-08-09
RU2019115303A3 (OSRAM) 2021-03-02
MY195369A (en) 2023-01-16
AU2017346974A1 (en) 2019-03-14
KR20190082229A (ko) 2019-07-09
JP2023025066A (ja) 2023-02-21
EP3529260A1 (en) 2019-08-28
MX2023001219A (es) 2023-03-03
RU2766354C2 (ru) 2022-03-15
AU2022204585A1 (en) 2022-07-21
TW201819402A (zh) 2018-06-01
JP7181208B2 (ja) 2022-11-30
AR109847A1 (es) 2019-01-30
PH12019500843A1 (en) 2019-12-02
US20220288183A1 (en) 2022-09-15
PE20191320A1 (es) 2019-09-24
CR20190249A (es) 2019-10-16
WO2018072031A1 (en) 2018-04-26
US11324815B2 (en) 2022-05-10
UY37448A (es) 2018-03-23
CA3037070A1 (en) 2018-04-26
EP3529260A4 (en) 2020-12-16
BR112019007796A2 (pt) 2019-09-03
RU2019115303A (ru) 2020-11-23
DOP2019000102A (es) 2019-07-15
CL2019001048A1 (es) 2019-08-30
IL265869A (en) 2019-06-30
SG11201901483QA (en) 2019-03-28
CN109843910A (zh) 2019-06-04
SG10201912431XA (en) 2020-02-27
NZ751880A (en) 2023-04-28
US20190216913A1 (en) 2019-07-18
MX2019004539A (es) 2019-06-12
RU2022100889A (ru) 2022-04-06

Similar Documents

Publication Publication Date Title
US11129884B2 (en) Bacterial vaccine components and uses thereof
Lin Novel approaches for Campylobacter control in poultry
JP2022078317A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓに対して免疫化するための組成物
Bartolini et al. Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro
US20220288183A1 (en) Vaccine constructs and uses thereof against staphylococcus infections
US10513544B2 (en) Group A streptococcus vaccine
JP2015529677A (ja) ワクチンとしてのＣｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅポリペプチド
Chen et al. Vaccination with a trivalent Klebsiella pneumoniae vaccine confers protection in a murine model of pneumonia
Huang et al. Biochemical and immunological characterization of truncated fragments of the receptor-binding domains of C. difficile toxin A
JP2015515486A (ja) 抗原および抗原の組み合わせ
HK40007546A (en) Vaccine constructs and uses thereof against staphylococcus infections
KR101680052B1 (ko) 탄저병의 예방 또는 치료를 위한 약제학적 조성물
EP2892552A1 (en) An immunogenic composition comprising an inactivated recombinant non-pathogenic bacterium
Lowry Identification of novel gene products associated with virulence of Brucella abortus using gene discovery and targeted approaches

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired